SG11202111809XA - Compositions and methods for use of cannabinoids for neuroprotection - Google Patents
Compositions and methods for use of cannabinoids for neuroprotectionInfo
- Publication number
- SG11202111809XA SG11202111809XA SG11202111809XA SG11202111809XA SG11202111809XA SG 11202111809X A SG11202111809X A SG 11202111809XA SG 11202111809X A SG11202111809X A SG 11202111809XA SG 11202111809X A SG11202111809X A SG 11202111809XA SG 11202111809X A SG11202111809X A SG 11202111809XA
- Authority
- SG
- Singapore
- Prior art keywords
- cannabinoids
- neuroprotection
- compositions
- methods
- Prior art date
Links
- 229930003827 cannabinoid Natural products 0.000 title 1
- 239000003557 cannabinoid Substances 0.000 title 1
- 229940065144 cannabinoids Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000004112 neuroprotection Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962838216P | 2019-04-24 | 2019-04-24 | |
PCT/CA2020/050547 WO2020215164A1 (en) | 2019-04-24 | 2020-04-24 | Compositions and methods for use of cannabinoids for neuroprotection |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202111809XA true SG11202111809XA (en) | 2021-11-29 |
Family
ID=72940570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202111809XA SG11202111809XA (en) | 2019-04-24 | 2020-04-24 | Compositions and methods for use of cannabinoids for neuroprotection |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230043428A1 (en) |
EP (1) | EP3958856A4 (en) |
JP (1) | JP7633179B2 (en) |
KR (1) | KR20220080045A (en) |
CN (1) | CN114007603A (en) |
AU (1) | AU2020261515A1 (en) |
CA (1) | CA3134764A1 (en) |
IL (1) | IL287536A (en) |
MX (1) | MX2021012960A (en) |
SG (1) | SG11202111809XA (en) |
WO (1) | WO2020215164A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115006404A (en) * | 2022-08-09 | 2022-09-06 | 昆药集团股份有限公司 | Pharmaceutical composition with optic nerve protection effect and application thereof |
US20240139272A1 (en) * | 2022-10-27 | 2024-05-02 | Kemin Industries, Inc. | Use of a spearmint extract for retina neurotrophism |
WO2024148117A2 (en) * | 2023-01-04 | 2024-07-11 | Florascience Inc. | Methods of treating neurodegenerative diseases or conditions |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2471987B (en) * | 2008-06-04 | 2012-02-22 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
AU2011329623A1 (en) * | 2010-11-18 | 2013-07-11 | Pier Pharmaceuticals | Low dose cannabinoid medicaments |
CA3135893C (en) | 2014-10-21 | 2023-11-14 | United Cannabis Corp. | Cannabis extracts and methods of preparing and using same |
MA41299A (en) * | 2014-12-30 | 2017-11-07 | Axim Biotechnologies Inc | OPHTHALMIC SOLUTIONS FOR THE TREATMENT OF GLAUCOMA AND CONJUNCTIVITIS |
US20170266153A1 (en) * | 2015-02-27 | 2017-09-21 | Ebbu, LLC | Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes |
CN107405314A (en) * | 2015-02-27 | 2017-11-28 | 埃布公司 | Composition comprising a combination of purified cannabinoids and at least one flavonoid, terpene or mineral |
BR112017018316A2 (en) * | 2015-02-27 | 2018-04-17 | Ebbu Llc | compositions comprising combinations of purified cannabinoids with at least one flavonoid, terpene or mineral |
EP3278100B1 (en) * | 2015-03-28 | 2023-06-14 | Tecan SP, Inc. | Methods and uses comprising solid phase extraction, derivatization with crown ethers, and mass spectrometry |
IL248149B (en) * | 2016-09-29 | 2020-03-31 | Garti Nissim | Dilutable formulations of cannbinoids and processes for their preparation |
IL265902B2 (en) | 2016-10-11 | 2024-04-01 | Gbs Global Biopharma Inc | Complex mixtures containing cannabinoids for the treatment of neurodegenerative diseases |
WO2018118197A1 (en) * | 2016-12-21 | 2018-06-28 | Richard Postrel | Healthier aging in domesticated animals |
JP7323458B2 (en) * | 2017-05-08 | 2023-08-08 | インメド ファーマシューティカルズ インコーポレイティド | eye drop delivery formulation |
WO2018205038A1 (en) | 2017-05-12 | 2018-11-15 | Tetra Bio-Pharma Inc. | Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling |
US20170348277A1 (en) * | 2017-08-02 | 2017-12-07 | Bryan Ray Ruiz | Cannabinoid formulation including a vasodilator and ocular delivery of the same |
-
2020
- 2020-04-24 CA CA3134764A patent/CA3134764A1/en active Pending
- 2020-04-24 AU AU2020261515A patent/AU2020261515A1/en active Pending
- 2020-04-24 CN CN202080046190.4A patent/CN114007603A/en active Pending
- 2020-04-24 KR KR1020217036628A patent/KR20220080045A/en active Pending
- 2020-04-24 EP EP20794650.0A patent/EP3958856A4/en active Pending
- 2020-04-24 US US17/606,003 patent/US20230043428A1/en active Pending
- 2020-04-24 JP JP2021563360A patent/JP7633179B2/en active Active
- 2020-04-24 SG SG11202111809XA patent/SG11202111809XA/en unknown
- 2020-04-24 WO PCT/CA2020/050547 patent/WO2020215164A1/en unknown
- 2020-04-24 MX MX2021012960A patent/MX2021012960A/en unknown
-
2021
- 2021-10-24 IL IL287536A patent/IL287536A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN114007603A (en) | 2022-02-01 |
MX2021012960A (en) | 2022-01-04 |
KR20220080045A (en) | 2022-06-14 |
CA3134764A1 (en) | 2020-10-29 |
US20230043428A1 (en) | 2023-02-09 |
AU2020261515A1 (en) | 2021-11-18 |
JP7633179B2 (en) | 2025-02-19 |
JP2022530471A (en) | 2022-06-29 |
EP3958856A4 (en) | 2023-01-25 |
EP3958856A1 (en) | 2022-03-02 |
IL287536A (en) | 2021-12-01 |
WO2020215164A1 (en) | 2020-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2597163B (en) | Cannabinoid compositions and methods of using | |
EP3790596A4 (en) | Oligonucleotide compositions and methods of use thereof | |
IL287536A (en) | Compositions and methods for use of cannabinoids for neuroprotection | |
EP3893917A4 (en) | Il-15 compositions and methods of use thereof | |
ZA202100780B (en) | Bismuth-thiol compositions and methods of use | |
IL276135A (en) | Compositions and methods of use | |
IL269590A (en) | Methods and compositions for reduction of immunogenicity | |
GB202105087D0 (en) | Microbial compositions and methods of use | |
GB2597170B (en) | Diluents for compositions of cannabinoids and uses thereof | |
EP3606493A4 (en) | Dental cement compositions and methods of use | |
SG11202011227VA (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
SG11202011041YA (en) | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof | |
IL283850A (en) | Cannabis compositions and methods | |
IL275739A (en) | Compositions for cryopreservation and methods of use thereof | |
IL287797A (en) | Oligosaccharide compositions and methods of use | |
IL283950A (en) | Methods and compositions for producing cannabinoids | |
EP3426238A4 (en) | Curcumin-based compositions&methods of use thereof | |
EP4054514A4 (en) | Compositions containing fenchols and methods of use | |
IL276680A (en) | Silica fiber compositions and methods of use | |
GB202009064D0 (en) | Compounds and methods of use | |
EP3920904A4 (en) | Compositions comprising cannabinoids and methods of use thereof | |
IL285367A (en) | Methods and compositions for inhibiting expression of cyp27a1 | |
EP3843721A4 (en) | Ophthalmic compositions and methods of use | |
EP3773497A4 (en) | Oxytocin compositions and methods of use | |
IL291538A (en) | Anti-aging compositions and methods of use thereof |